4,4,4-trifluoro-2-(triphenyl-λ⁵-phosphanylidene)butyric acid ethyl ester | 769169-70-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4,4-trifluoro-2-(triphenyl-λ⁵-phosphanylidene)butyric acid ethyl ester
• 英文别名: 4,4,4-Trifluoro-2-(triphenyl-l5-phosphanylidene)-butyric acid ethyl ester；4,4,4-Trifluoro-2-(triphenyl-lambda5-phosphanylidene)-butyric acid ethyl ester；ethyl 4,4,4-trifluoro-2-(triphenyl-λ5-phosphanylidene)butanoate
• CAS: 769169-70-2
• 化学式: C₂₄H₂₂F₃O₂P
• 分子量: 430.406
• InChiKey: JLBQWIZNYWAPMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  498.6±55.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,4,4-trifluoro-2-(triphenyl-λ⁵-phosphanylidene)butyric acid ethyl ester 在 5%-palladium/activated carbon 、 氢气 、 碳酸氢钠 、 magnesium sulfate 作用下， 以 四氢呋喃 、 甲基叔丁基醚 、 水 为溶剂， 10.0~75.0 ℃ 、344.75 kPa 条件下， 反应 17.17h， 生成 4,4,4-trifluoro-2-(2,2,2-trifluoroethyl)butyric acid ethyl ester
  参考文献：
  名称：

  实用的不对称合成修饰的戴维斯协议的三氟甲基的氨基酯。

  摘要：

  提出了从1,1,1-三氟-3-碘丙烷开始的氨基酯1的实用合成方法。已发现使用Ti（O i -Pr）4作为路易斯酸将中间醛8与（S）-（+）-对甲苯亚磺酰胺缩合是至关重要的。描述了可再现且高产率的水合醛与磷内酯4的Wittig反应的条件，该条件似乎具有普遍的适用性。

  DOI：

  10.1021/op700259d
• 作为产物：
  描述：

  氯甲酸乙酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以89%的产率得到4,4,4-trifluoro-2-(triphenyl-λ⁵-phosphanylidene)butyric acid ethyl ester
  参考文献：
  名称：

  Methods for preparing sulfonamide compounds

  摘要：

  提供了制备以下结构的取代苯磺酰胺化合物的方法：或其药用可接受盐，其中，R1-R7在此处定义。还提供了制备以下结构化合物的方法：其中，R9，m，n，p，r和s在此处定义。

  公开号：

  US20070249723A1

文献信息

• Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
  申请人：Porte Alexander Michael

  公开号：US20070249722A1

  公开（公告）日：2007-10-25

  A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R 1 -R 7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

  提供了Formula (I)的化合物，或其药用可接受的盐和/或水合物或前药，其中Formula (I)具有以下结构： 在此定义了R1-R7。这些化合物在治疗从阿尔茨海默病、淀粉样血管病、脑淀粉样血管病、全身性淀粉样病、荷兰型遗传性脑出血伴淀粉样病、包涵体肌炎、轻度认知障碍（MCI）和唐氏综合征等疾病的药物中对受试者有用。
• Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
  申请人：Wyeth

  公开号：US20040198778A1

  公开（公告）日：2004-10-07

  Compounds of Formula (I), 1 are provided where T is CHO, CON, or C(OH)R 1 R 2 ; R 1 and R 2 are hydrogen, optionally substituted lower alkyl, CF 3 , optionally substituted alkenyl, or optionally substituted alkynyl; R 3 is hydrogen or optionally substituted lower alkyl; R 4 is (CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), or (F) n cycloalkyl; n=1-3; R 5 is hydrogen, halogen, CF 3 , diene fused to Y when Y═C, or substituted diene fused to Y when Y═C; W, Y and Z are C, CR 6 or N where at least one of W, Y or Z are C; R 6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO 2 , or NR 7 ; R 7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R 8 is lower alkyl, CF 3 , or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了具有式(I)的化合物，其中T为CHO、CON或C(OH)R1R2；R1和R2为氢、可选择取代的较低烷基、CF3、可选择取代的烯烃或可选择取代的炔烃；R3为氢或可选择取代的较低烷基；R4为(CF3)n烷基、(CF3)n(取代烷基)、(CF3)n烷基苯基、(CF3)n烷基(取代苯基)或(F)n环烷基；n=1-3；R5为氢、卤素、CF3、与Y融合的双烯烃（当Y为C时）、或与Y融合的取代双烯烃（当Y为C时）；W、Y和Z为C、CR6或N，其中至少有一个为C；R6为氢、卤素或可选择取代的较低烷基；X为O、S、SO2或NR7；R7为氢、可选择取代的较低烷基、可选择取代的苄基或可选择取代的苯基；R8为较低烷基、CF3或可选择取代的苯基。还描述了制备和使用这些化合物来抑制β淀粉样蛋白的产生，以及治疗阿尔茨海默病和唐氏综合征的方法。
• [EN] FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF<br/>[FR] SULFONAMIDES HETEROCYCLIQUES CONTENANT DES FLUORO-ET-TRIFLUOROALKYLES, INHIBITEURS DE LA PRODUCTION DE BETA AMYLOIDE, ET LEURS DERIVES
  申请人：WYETH CORP

  公开号：WO2004092155A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I), are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了化合物公式(I)，其中T为CHO、COR8或C(OH)R1R2；R1和R2为氢、可选取代的低碳基、CF3、可选取代的烯基或可选取代的炔基；R3为氢或可选取代的低碳基；R4为(CF3)n烷基、(CF3)n(取代烷基)、(CF3)n烷基苯基、(CF3)n烷基(取代苯基)或(F)ncycloalkyl；n=1-3；R5为氢、卤素、CF3、与Y融合的双烯烃（当Y=C时）或取代的与Y融合的双烯烃（当Y=C时）；W、Y和Z为C、CR6或N，其中至少有一个为C；R6为氢、卤素或可选取代的低碳基；X为O、S、SO2或NR7；R7为氢、可选取代的低碳基、可选取代的苯甲基或可选取代的苯基；R8为低碳基、CF3或可选取代的苯基。还描述了制备和使用这些化合物以抑制β淀粉样蛋白的产生以及治疗阿尔茨海默病和唐氏综合症的方法。
• TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS
  申请人：Porte Alexander Michael

  公开号：US20090221711A1

  公开（公告）日：2009-09-03

  A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R 1 -R 7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

  提供了公式（I）的化合物，或其药学上可接受的盐和/或水合物或前药，其中公式（I）具有结构：其中R1-R7在此定义。这些化合物在治疗以下疾病的药物中有用，所述疾病选自阿尔茨海默病，淀粉样血管病，脑淀粉样血管病，全身性淀粉样变性，荷兰型遗传性脑出血伴有淀粉样沉积，包涵体肌病，轻度认知障碍（MCI）和唐氏综合症。
• FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF
  申请人：Kreft Anthony Frank

  公开号：US20090227667A1

  公开（公告）日：2009-09-10

  Compounds of Formula (I), are provided where T is CHO, COR 8 , or C(OH)R 1 R 2 ; R 1 and R 2 are hydrogen, optionally substituted lower alkyl, CF 3 , optionally substituted alkenyl, or optionally substituted alkynyl; R 3 is hydrogen or optionally substituted lower alkyl; R 4 is (CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), or (F) n cycloalkyl; n=1-3; R 5 is hydrogen, halogen, CF 3 , diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CR 6 or N where at least one of W, Y or Z are C; R 6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO 2 , or NR 7 ; R 7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R 8 is lower alkyl, CF 3 , or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了化学式（I）的化合物，其中T为CHO，COR8或C（OH）R1R2; R1和R2为氢，可选取代的低级烷基，CF3，可选取代的烯基或可选取代的炔基; R3为氢或可选取代的低级烷基; R4为（CF3）n烷基，（CF3）n（取代烷基），（CF3）n烷基苯基，（CF3）n烷基（取代苯基）或（F）n环烷基; n = 1-3; R5为氢，卤素，CF3，与Y融合的二烯或与Y融合的取代二烯，当Y = C时; W，Y和Z为C，CR6或N，其中至少有一个为C; R6为氢，卤素或可选取代的低级烷基; X为O，S，SO2或NR7; R7为氢，可选取代的低级烷基，可选取代的苄基或可选取代的苯基; R8为低级烷基，CF3或可选取代的苯基。还描述了制备和使用这些化合物来抑制β淀粉样蛋白生成以及治疗阿尔茨海默病和唐氏综合症的方法。